Top Holdings*as of 2/1/2012 |
|
|---|---|
| Name | % of Fund |
| AMGEN INC | 8.46% |
| ALEXION PHARMACEUTICALS INC | 6.57% |
| CELGENE CORP | 6.30% |
| GILEAD SCIENCES INC | 5.63% |
| REGENERON PHARMACEUTICALS | 5.42% |
| BIOGEN IDEC INC | 4.99% |
| TEVA PHARMACEUTICAL-SP ADR | 4.89% |
| PERRIGO CO | 3.81% |
| VERTEX PHARMACEUTICALS INC | 3.31% |
| MYLAN INC | 2.89% |
| Total | 52.27% |
|
Sector Breakdownas of 2/1/2012*
|
|||||
|---|---|---|---|---|---|
| Sector | % of Fund | ||||
|
Biotechnology
69.24%
|
|||||
|
Pharmaceuticals
30.76%
|
|||||
|
S-T Securities
0.05%
|
|||||
Avg. Annualized Total Returns (NAV)qtr. as of 12/31/2011 | |||||
|---|---|---|---|---|---|
1 Year |
3 Years |
5 Years |
10 Years |
Since Inception | |
| IBB | 11.86% | 14.08% | 6.23% | 1.49% | 0.51% |
| Index |
11.81% | 14.14% | 6.32% | 1.79% | 0.78% |
Yield as of 1/31/2012 |
||
|---|---|---|
| Description | % | |
| 30-Day SEC Yield |
0.07% | |
| 12-Month Yield as of 1/31/2012 |
0.01% | |
| Fundamentals & Risk as of 12/30/2011 | ||
|---|---|---|
| Description | Value | |
| Price to Earnings Ratio | 27.21 | |
| Price to Book Ratio | 8.53 | |
| Beta vs S&P 500 | 0.66 | |
| Standard Deviation (3 year) |
18.60% | |
| Profile as of 2/3/2012 | |
|---|---|
| Description | Value |
| Total Net Assets | $1,693,222,093 |
| Expense Ratio | 0.48% |
| Shares Outstanding | 14,050,000 |
Number of Holdings as of 2/1/2012 |
119 |
| Inception Date | 2/5/2001 |
| Related Index | NBI |
Net Asset Value as of 2/3/2012 |
$120.51
|
|
Price as of 2/2/2012 |
$119.21
|
| Fees & Expenses | |||
|---|---|---|---|
| Expense Type | % | ||
| Management Fees | 0.48% | ||
+ |
Acquired Fees & Expenses | 0.00% | |
= |
Total Annual Fund Operating Expenses | 0.48% | |
| Trading Information | ||
|---|---|---|
| Identifier Type | Symbol | |
| Ticker | IBB | |
| Related Index | NBI | |
| NAV | IBB.NV | |
| Underlying Trading Value | IBB.IV | |
| Shares Outstanding | IBB.SO | |
| Estimated Cash | IBB.EU | |
| Total Cash | IBB.TC | |
| CUSIP | 464287556 | |
| Options Available | ||
